Aurobindo Pharma Ltd. (AUROPHARM): Aurobindo Pharma 52 Week High Streak: AUROPHARM Near Peak Again

Aurobindo Pharma 52 Week High Streak has now continued for its second straight session, with the stock trading within 2% of its 52-week high and moving up 2.83% across the streak. Aurobindo Pharma Ltd. (AUROPHARM) is being watched near a 52-week peak of Rs 1,700.05, while the latest trade stood at Rs 1,687.45. The latest Univest data confirms the price pattern, but it does not establish a company-specific catalyst for the repeated near-high trading.

At 18 September 2026 at 1:18 PM IST, the stock was up Rs 3.50 from the previous close of Rs 1,683.95, after opening at Rs 1,687.85 and touching a low of Rs 1,676.40. Turnover stood at Rs 1.49 crore, while market capitalisation was Rs 94,419.51 crore. For readers tracking Aurobindo Pharma Share Price, the key point is not just the day’s small move but the fact that the stock has stayed close to its yearly high on consecutive sessions.

Aurobindo Pharma 52 Week High Streak: Consecutive High Analysis

Metric	Value
Current Price	Rs 1,687.45
Previous Close	Rs 1,683.95
Today's Move	+Rs 3.5 (+0.21%)
Open	Rs 1,687.85
High	Rs 1,700.05
Low	Rs 1,676.4
Turnover	Rs 1.49 crore
Market Capitalisation	Rs 94,419.51 crore

Aurobindo Pharma Ltd. (AUROPHARM) traded at Rs 1,687.45 versus the previous close of Rs 1,683.95, a rise of 0.21%. The stock opened at Rs 1,687.85, reached a high of Rs 1,700.05 and touched a low of Rs 1,676.4.

The latest Aurobindo Pharma share price update shows a modest intraday move, with the stock last trading at Rs 1,687.45 versus the previous close of Rs 1,683.95. That translates into a gain of Rs 3.50, or 0.21%, and keeps AUROPHARM near its one-year high zone. The session opened at Rs 1,687.85, moved to a high of Rs 1,700.05 and a low of Rs 1,676.40, which places the trade near the upper end of the day’s range.

This matters because the stock is not being discussed only for one price point, but for its repeated stay near the peak. Aurobindo Pharma stock news flow today is therefore best read as a near-high continuation rather than a fresh one-off spike. The turnover of Rs 1.49 crore gives a factual read on traded value, while the market cap of Rs 94,419.51 crore places the company among the larger listed names in healthcare. For investors following Aurobindo Pharma stock performance, the session adds another data point to the broader near-52-week-high streak.

Aurobindo Pharma 52 Week High Streak: Consecutive High Analysis

Aurobindo Pharma 52 Week High Streak is now a two-session pattern, and that is the main story. The stock has traded within 2% of its 52-week high for its second straight session, with the cumulative move across that streak at 2.83%. That is the most useful multi-session signal here because it captures the full near-peak run rather than only today’s change.

The earlier breakout on 17 September 2026 is best treated as the anchor session, while today confirms that AUROPHARM has remained close to the same upper price band. In practical search terms, this is what investors mean when they look for Aurobindo Pharma 52 Week High For second straight session or Aurobindo Pharma Back To Back 52 Week Highs. The latest reading suggests continuity in price behaviour, not a new conclusion about direction beyond the fact that the stock remains near its yearly high.

The other important reference point is the distance from the earlier 52-week peak to the current one-year high level. Because only the present high of Rs 1,700.05 is provided here, the article can identify the latest peak but should not speculate on how much higher it sits versus a prior high that is not supplied. That keeps the 52 Week High Streak analysis factual and precise.

What the Repeated 52-Week Highs Show

Repeated near-high trading tells readers that the stock has stayed in a narrow zone near its yearly high for more than one session, which is structurally different from a one-day breakout story. For Aurobindo Pharma, the important fact is the persistence of the pattern: the price remains within 2% of the 52-week high, and that has now happened on consecutive sessions.

What the repeated 52-week highs show is the market’s current willingness to keep the stock near the upper end of its annual range, while the latest Univest data does not identify a specific news trigger behind the move. That distinction matters. The pattern is real, but the reason for it is not established by the numbers alone.

For those searching phrases like Is Aurobindo Pharma Overbought or Aurobindo Pharma New One Year High, the most careful answer is that this article confirms a near-high streak, not a valuation call or a technical reversal call. The event is best interpreted as a sequence of sustained near-peak trades, which can matter for stock tracking, watchlist management and short-term market monitoring.

Aurobindo Pharma Ltd. (AUROPHARM) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 94,419.51 crore
P/E Ratio	26.1x
P/B Ratio	2.49x
ROE	9.93%
ROCE	12.76%
EPS	Rs 64.52
Book Value Per Share	Rs 676.49
Dividend Yield	0.24%

Aurobindo Pharma Ltd. (AUROPHARM) fundamental metrics show P/E 26.1x, P/B 2.49x, ROE 9.93%, ROCE 12.76%. These figures provide context only and are not a buy or sell signal.

Aurobindo Pharma Ltd. has a market capitalisation of Rs 94419.51 crore, which gives readers a sense of company size before judging valuation. On valuation, P/E at 26.1x, P/B at 2.49x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 9.93% and ROCE of 12.76%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 64.52, book value per share of Rs 676.49, dividend yield of 0.24%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 28.19x, median ROE of 11.78%, median ROCE of 13.65%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Pharmaceuticals & Drugs
Benchmark Scope	same industry
Company P/E Ratio	26.1x
Benchmark Median P/E	28.19x
Benchmark Average P/E	37.62x
Benchmark P/E Range	0x to 417.17x
Company P/B Ratio	2.49x
Benchmark Median P/B	3.1x
Company ROE	9.93%
Benchmark Median ROE	11.78%
Company ROCE	12.76%
Benchmark Median ROCE	13.65%
Company Market Capitalisation	Rs 94,419.51 crore
Benchmark Median Market Cap	Rs 733.35 crore

Aurobindo Pharma Ltd. (AUROPHARM) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.

Aurobindo Pharma Ltd. (AUROPHARM) has a P/E ratio of 26.1x, which is below the benchmark median of 28.19x, a difference of -7.41%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

Aurobindo Pharma Ltd. (AUROPHARM) has a ROE of 9.93%, which is below the benchmark median of 11.78%, a difference of -15.7%. Aurobindo Pharma Ltd. (AUROPHARM) has a ROCE of 12.76%, which is below the benchmark median of 13.65%, a difference of -6.52%.

Track stocks reaching yearly peaks through the Univest 52-week-high screener. The peer table below provides the company-level comparison.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Lupin Ltd.	LUPIN	93,611.47	17.3	4.02	27.11	28.86
Dr. Reddy's Laboratories Ltd.	DRREDDY	95,591.76	30.36	2.56	11.69	13.75
Mankind Pharma Ltd.	MANKIND	92,852.54	46.41	5.63	12.69	13.24
Laurus Labs Ltd.	LAURUSLABS	1,02,983.51	96.68	18.75	18.31	18.2
Cipla Ltd.	CIPLA	1,09,848.55	32.89	3.15	11.83	16

Aurobindo Pharma Ltd. (AUROPHARM) has a P/E ratio of 26.1x compared with the displayed peer median of 32.89x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 9.93% compares with a peer median of 12.69% across the companies shown in the table. ROCE stood at 12.76% versus the displayed peer median of 16%, providing a capital-efficiency comparison. Aurobindo Pharma Ltd. (AUROPHARM) has a market capitalisation of Rs 94,419.51 crore. Among the 5 peers shown, 3 have a larger market capitalisation.

Why Investors Are Watching Aurobindo Pharma

• Aurobindo Pharma 52 Week High Streak has extended for a second straight session.
• The stock is still trading within 2% of its 52-week high, keeping AUROPHARM in focus.
• The cumulative move across the streak stands at 2.83%.
• The latest market cap is Rs 94,419.51 crore, which makes the stock widely tracked in Healthcare.
• Valuation sits below the industry median on both P/E and P/B.

About Aurobindo Pharma Ltd.

Aurobindo Pharma Ltd. is a Healthcare company in the Pharmaceuticals & Drugs industry and is listed on both NSE and BSE as AUROPHARM. The stock is being watched because it has stayed near its yearly high for consecutive sessions, while its market capitalisation remains close to Rs 94,000 crore.

The company’s current financial snapshot includes a P/E of 26.1, a P/B of 2.49, ROE of 9.93%, ROCE of 12.76%, EPS of Rs 64.52 and book value of Rs 676.49. These figures help place the stock’s near-52-week-high behavior in a broader company-specific context.

Track Aurobindo Pharma on Univest

Track Aurobindo Pharma on Univest to follow the live share price, market cap, stock performance and company news in one place. Readers monitoring Aurobindo Pharma stock news can use the stock page to keep an eye on the next move around the one-year high zone and compare the latest numbers with sector and peer references.

If you are screening Stocks In News Today, AUROPHARM remains one of the names to watch because the repeated near-high pattern is now established for a second straight session. That makes the Aurobindo Pharma Share Price a useful watchlist item for market tracking.

Frequently Asked Questions

What is Aurobindo Pharma 52 Week High Streak?

Ans. It refers to the stock staying within 2% of its 52-week high on consecutive sessions. For Aurobindo Pharma, that streak is now at a second straight session, with the latest peak at Rs 1,700.05.

How many sessions has Aurobindo Pharma traded near its 52-week high?

Ans. Aurobindo Pharma has traded within 2% of its 52-week high for two consecutive sessions. That is why the stock is being discussed as a near-peak streak rather than only a one-day move.

What is the cumulative move across the Aurobindo Pharma 52 Week High Streak?

Ans. The cumulative move across the streak is 2.83%. This is the best single figure for understanding the full pattern because it captures the broader near-high movement across both sessions.

Did Aurobindo Pharma set a new 52-week high today?

Ans. The stock traded near its 52-week high, but the event here is a repeated near-high streak. The latest high supplied is Rs 1,700.05, and the article does not treat this as a new all-time high.

Is there a confirmed company-specific catalyst behind the move?

Ans. No company-specific catalyst is confirmed by the latest Univest data. The figures show the price pattern and the repeated near-high trading, but they do not identify a reason for the continuation.

How does Aurobindo Pharma compare with sector valuations?

Ans. Aurobindo Pharma trades below the industry median on P/E and P/B in the selected healthcare peer set. That places it in a relatively moderate valuation position versus many listed pharmaceutical names.

What should investors track next in Aurobindo Pharma share price movement?

Ans. Investors should track whether the stock continues to remain near its yearly high, how the price behaves versus the latest peak of Rs 1,700.05, and whether any new company updates appear alongside the streak.

Why is Aurobindo Pharma in stock news today?

Ans. It is in stock news today because the share price has remained near its 52-week high for a second straight session. That repeated pattern places AUROPHARM on shortlists for 52 Week High Stocks and market watchers.

Track Aurobindo Pharma Ltd. (AUROPHARM) Share Price on Univest

Use Aurobindo Pharma Ltd. (AUROPHARM) live share-price page, Univest 52-week-high screener, Univest market blogs to review live stock data, yearly-high lists and related market analysis.